The preparation Neurexan® for the treatment of anxiety disorders in multimorbid patients. Resolution of the Council of Experts (October 27, 2023)

Nataliya A. Ermolenko , Valeriya A. Bykova , Olga V. Ulyanova , Lyudmila V. Tribuntseva , Olga V. Troshina

For citation:

Abstract

Stress disorders are a global public health problem, having a significant impact on patients and society. Chronic stress can lead to long-term consequences, including mental and physical illness. The body's first response to acute stress is characterized by the appearance of anxiety, but beyond a certain level, anxiety becomes maladaptive. Anxiety worsens the quality of life and adaptation of patients, complicates the course of comorbid pathology and its diagnosis. In the review anxiety disorders in patients with multiple sclerosis, Parkinson's disease, and chronic pain syndromes discussed. A significant deterioration in the course and prognosis of the neurological disease in combination with anxiety disorders in multimorbid patients has been shown. Treatment of anxiety includes psychotherapy, the use of antidepressants, and short courses of benzodiazepines. Neurexan® as the safe and effective drug that does not interact with other drugs and has a favorable tolerability profile can be recommended to patients with multimorbid pathologies to correct emotional disorders, reduce anxiety and improve sleep.
Key words: stress, anxiety, multimorbidity, multiple sclerosis, Parkinson's disease, chronic pain, Neurexan.

References

1. Gradus JL. Prevalence and prognosis of stress disorders: A review of the epidemiologic literature. Clin Epidemiol. 2017; (9): 251–60. DOI: 10.2147/CLEP.S106250

2. Milczarek, Malgorzata & Schneider, Elke & González, Eusebio. (2009). OSH in Figures: Stress at Work – Facts and Figures.

3. Medicine Net. Medical definition of stress. https://www.medicinenet. com/stress/article.htm

4. Slavich GM. Life Stress and Health: A Review of Conceptual Issues and Recent Findings. Teach Psychol. 2016; 43 (4): 346–55. DOI: 10.1177/0098628316662768

5. Brenner SL, Jones JP, Rutanen-Whaley RH et al. Evolutionary Mismatch and Chronic Psychological Stress. J Evol Med 2015; (3): 1–11.

6. American Institute of Stress. What is stress? https://www.stress.org/ daily-life/DOI:10.4303/jem/235885

7. Bent S, Padula A, Moore D et al. Valerian for sleep: A systematic review and meta-analysis. Am J Med 2006; 119 (12): 1005–12. DOI: 10.1016/j.amjmed.2006.02.026

8. Гуров В.А., Медведев В.Э. Тревожные расстройства в общей врачебной практике: аспекты клиники и терапии. Архивъ внутренней медицины. 2011; (2): 15–9. DOI: 10.20514/2226-6704-2011-0-2-15-19

Gurov VA, Medvedev VE. Anxiety disorders in general medical practice: clinical and therapeutic aspects. Archives of Internal Medicine 2011; (2): 15–9. DOI: 10.20514/2226-6704-2011-0-2-15-19 (in Russian).

9. Stubbs B, Vancampfort D, Veronese N et al. Multimorbidity and perceived stress: a population-based cross-sectional study among older adults across six low- and middle-income countries. Maturitas 2018; 1 (107): 84–91. DOI:10.1016/j.maturitas.2017.10.007

10. Moussavi S, Chatterji S, Verdes E et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007; 370 (9590): 851–8. DOI: 10.1016/S0140-6736(07)

61415-9

11. Broussard JL, Ehrmann DA, Van Cauter E et al. Impaired insulin signaling in human adipocytes after experimental sleep restriction: A randomized, crossover study. Ann Intern Med 2012; 157 (8): 549–57. DOI: 10.7326/0003-4819-157-8-201210160-00005

12. Zefferino R, Di Gioia S, Conese M. Molecular links between endocrine, nervous, and immune system during chronic stress. Brain Behav 2021; 11 (2): e01960. DOI: 10.1002/brb3.1960

13. Oken BS, Chamine I, Wakeland W. A systems approach to stress, stressors, and resilience in humans. Behav Brain Res 2015; 282: 144–54. DOI: 10.1016/j.bbr.2014.12.047

14. Скоромец А.А., Заславский Л.Г. Тревожность как один из факторов, определяющих скорость прогрессирования рассеянного склероза. Неврологический вестник. 2000; 32 (3): 5–9.

Skoromets AA, Zaslavsky LG. Anxiety as one of the factors determining the rate of progression of multiple sclerosis. Neurology Bulletin. 2000; 32 (3): 5–9 (in Russian).

15. Weintraub D, Aarsland D, Chaudhuri KR et al. The neuropsychiatry of Parkinson's disease: advances and challenges. Lancet Neurol 2022; 21 (1): 89–102. DOI: 10.1016/S1474-4422(21)00330-6

16. Левин О.С. Болезнь Паркинсона как нейропсихиатрическое заболевание. Consilium Medicum. 2011; (2): 27–31.

Levin OS. Parkinson's disease as a neuropsychiatric disease. Consilium Medicum. 2011; (2): 27–31 (in Russian).

17. Нодель М.Р. Влияние нервно-психических нарушений на качество жизни пациентов с болезнью Паркинсона. Неврологический журнал. 2015; (1): 20–5. DOI: 10.18821/1560-9545-2015-20-

120-27

Nodel МR. The impact of neuropsychiatric symptoms on quality of life of patients with parkinsons disease. Neurological journal. 2015; (1): 20–5 DOI: 10.18821/1560-9545-2015-20-120-27 (in Russian).

18. Медведева Л.А., Загорулько О.И., Гнездилов А.В. Хроническая боль: эпидемиология и социально-демографические характеристики пациентов клиники боли центра хирургии. Клиническая и экспериментальная хирургия. 2016; 3 (13): 36–43.

Medvedeva LA, Zagorulko OI, Gnezdilov AV. Chronic pain: epidemiology and socio-demographic characteristics of patients at the pain clinic of the surgery center. Clinical and Experimental Surgery. Petrovsky journal. 2016; 3 (13): 36–43 (in Russian).

19. Оганов Р.Г., Драпкина О.М. Полиморбидность: закономерности формирования и принципы сочетания нескольких заболеваний у одного пациента. Кардиоваскулярная терапия и профилактика. 2016; 15 (4): 4–9. DOI: 10.15829/1728-8800-2016-4-4-9

Oganov RG, Drapkina OM. Polymorbidity: specifics of co-development and concomitance of several diseases in one patient. Cardiovascular therapy and prevention. 2016; 15 (4): 4–9. DOI: 10.15829/1728-8800-2016-4-4-9 (in Russian).

20. Драпкина О.М., Шутов А.М., Ефремова Е.В. Коморбидность, мультиморбидность, двойной диагноз – синонимы или разные понятия? Кардиоваскулярная терапия и профилактика. 2019; 18 (2): 65–9. DOI: 10.15829/1728-8800-2019-2-65-69

Drapkina OM, Shutov AM, Efremova EV Comorbidity, multimorbidity, dual diagnosis – synonyms or different terms? Cardiovascular therapy and prevention. 2019; 18 (2): 65–9. DOI: 10.15829/1728-8800-2019-2-65-69 (in Russian).

21. Skou ST, Mair FS, Fortin M et al. Multimorbidity. Nat Rev Dis Primers 2022; 8 (1): 48. DOI: 10.1038/s41572-022-00376-4

22. Boyd CM, Fortin M. Future of multimorbidity research: How should understanding of multimorbidity inform health system design? Public Health Rev 2010; 32 (2): 451–74.

23. Marengoni A, Angleman S, Melis R et al. Ageing with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011; 10 (4): 430–9. DOI: 10.1016/j.arr.2011.03.003

24. Valderas JM, Starfield B, Sibbald B et al. Defining comorbidity: implications for understanding health and health services. Ann Fam Med 2009; 7 (4): 357–63. DOI: 10.1370/afm.983

25. Эбзеева Е.Ю., Остроумова Н.А., Шаталова С.В. и др. Лекарственно-индуцированная тревога. Клиническая фармакология. Лечебное дело. 2020; (4): 14–27. DOI: 10.24412/2071-5315-2020-12267

Ebzeeva EYu, Ostroumova OD, Shatalova NA et al. Drug-induced Anxiety. Lechebnoe Delo journal. 2020; (4): 14–27. DOI: 10.24412/2071-5315-2020-12267 (in Russian).

26. Gerlach LB, Wiechers IR, Maust DT. Prescription Benzodiazepine Use Among Older Adults: A Critical Review. Harv Rev Psychiatry 2018; 26 (5): 264–73. DOI: 10.1097/HRP.0000000000000190

27. Hübner R, Van Haselen R, Klein P. Effectiveness of the homeopathic preparation Neurexan® compared with that of commonly used valerian-based preparations for the treatment of nervousness/restlessness – An observational study. Sci World J 2009; (9): 733–45. DOI: 10.1100/tsw.2009.95

28. Баранцевич Е.Р., Курушина О.В., Ахмадеева Л.Р. и др. Биорегуляционный препарат Ньюрексан® в лечении тревожности и диссомнии. Резолюция Совета экспертов (8 июня 2023 г.). Журнал неврологии и психиатрии им. С.С. Корсакова. 2023; 123 (7): 143–6. DOI: 10.17116/jnevro2023123071143

Barantsevich ER, Kurushina OV, Akhmadeeva LR et al. Bioregulatory drug Newrexan® in the treatment of anxiety and dissomnia. Resolution of the Council of Experts (June 8, 2023). S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2023; 123 (7): 143–6. DOI: 10.17116/jnevro2023123071143 (in Russian).

29. Maeng L, Milad M. Sex differences in anxiety disorders: Interactions between fear, stress, and gonadal hormones. Horm Behav 2015; (76): 106–17. DOI: 10.1016/j.yhbeh.2015.04.002

30. Waldschütz R, Klein P. The homeopathic preparation Neurexan® vs. valerian for the treatment of insomnia: An observational study. Sci World J 2008; (8): 411–20. DOI:10.1100/tsw.2008.61

For citation:Ermolenko NA, Bykova VA, Ulyanova OV, Tribuntseva LV, Troshina OV. The preparation Neurexan® for the treatment of anxiety disorders in multimorbid patients. Resolution of the Council of Experts (October 27, 2023). Clinical analysis in general medicine. 2023; 4 (10): 65–70 (In Russ.). DOI: 10.47407/kr2023.4.10.00343

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice